Abstract Azacitidine+ venetoclax, decitabine+ venetoclax, and low-dose cytarabine+
venetoclax are now standard treatments for newly diagnosed older or unfit patients with …

Older patients with acute myeloid leukemia (AML) respond poorly to standard induction
therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells …

Venetoclax is approved for older untreated acute myeloid leukemia (AML) patients.
Venetoclax was available prior to approval off-label. We assessed our single-institution off …

This analysis represents the longest‐term follow‐up for patients with acute myeloid leukemia
(AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly …

PURPOSE Effective treatment options are limited for patients with acute myeloid leukemia
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …

Venetoclax (VEN) is a selective BCL-2 inhibitor that has been shown to be effective when
used in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) for …

Venetoclax‐azacitidine is approved for treatment of patients with newly diagnosed acute
myeloid leukemia (AML) ineligible for intensive chemotherapy based on the interim overall …

PURPOSE The combination of venetoclax and 5-azacitidine (5-AZA) for older or unfit
patients with acute myeloid leukemia (AML) improves remission rates and survival …

The clinical benefit of adding venetoclax (VEN) to hypomethylating agents or low-dose
cytarabine in older and/or unfit patients with newly diagnosed acute myeloid leukemia (AML) …

Recent clinical data have shown a synergistic effect of venetoclax in combination with the
hypomethylating agents (HMA) azacitidine and decitabine (complete remission [CR]/CR with …